- Previous Close
0.7950 - Open
0.7550 - Bid 0.8000 x --
- Ask 0.8500 x --
- Day's Range
0.7550 - 0.8000 - 52 Week Range
0.6400 - 1.2500 - Volume
72,641 - Avg. Volume
2,474 - Market Cap (intraday)
39.048M - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
20.00 - EPS (TTM)
0.0400 - Earnings Date Feb 20, 2025
- Forward Dividend & Yield 0.09 (10.63%)
- Ex-Dividend Date Sep 6, 2024
- 1y Target Est
--
Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through two segments: Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment offers specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, biological, and cell gene therapies depot services. The Cord Blood and Tissues Storage segment provides long term storage solutions for cord blood and tissue samples. The company serves research, medical, pharmaceutical, and biotechnology industries. Cryosite Limited was incorporated in 1999 and is based in South Granville, Australia.
www.cryosite.comRecent News: CTE.AX
View MorePerformance Overview: CTE.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTE.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTE.AX
View MoreValuation Measures
Market Cap
39.05M
Enterprise Value
36.92M
Trailing P/E
21.28
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.04
Price/Book (mrq)
29.78
Enterprise Value/Revenue
2.87
Enterprise Value/EBITDA
12.02
Financial Highlights
Profitability and Income Statement
Profit Margin
14.26%
Return on Assets (ttm)
6.75%
Return on Equity (ttm)
87.09%
Revenue (ttm)
12.85M
Net Income Avi to Common (ttm)
1.83M
Diluted EPS (ttm)
0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
4.49M
Total Debt/Equity (mrq)
179.79%
Levered Free Cash Flow (ttm)
2.03M